Shares of Consort Medical plc (NASDAQ:CSRMY) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Zacks has also given Consort Medical plc an industry rank of 119 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research downgraded Consort Medical plc from a “buy” rating to a “hold” rating in a report on Tuesday, August 15th.

Shares of Consort Medical plc (NASDAQ:CSRMY) opened at $14.05 on Friday.

TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/04/consort-medical-plc-csrmy-given-consensus-recommendation-of-strong-buy-by-brokerages.html.

About Consort Medical plc

Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.

Get a free copy of the Zacks research report on Consort Medical plc (CSRMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Consort Medical plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical plc and related companies with MarketBeat.com's FREE daily email newsletter.